IMO 2125 + ribavirin versus peginterferon alfa-2a + ribavirin in patients with hepatitis C stratified for IL28B genotype.
Phase of Trial: Phase II
Latest Information Update: 25 Feb 2012
At a glance
- Drugs IMO 2125; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 25 Feb 2012 Actual end date 20 Jan 2012 added as reported by EudraCT.
- 25 Feb 2012 Status changed from suspended to discontinued as reported by EudraCT.
- 10 May 2011 Actual initiation date 8 Apr 2011 added, trial location Hungary added as reported by European Clinical Trials Database record.